Haemonetics Corporation (HAE)
| Market Cap | 2.94B |
| Revenue (ttm) | 1.32B |
| Net Income (ttm) | 175.44M |
| Shares Out | 46.47M |
| EPS (ttm) | 3.65 |
| PE Ratio | 17.34 |
| Forward PE | 12.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 620,627 |
| Open | 61.72 |
| Previous Close | 62.24 |
| Day's Range | 61.72 - 64.05 |
| 52-Week Range | 47.32 - 87.32 |
| Beta | 0.27 |
| Analysts | Buy |
| Price Target | 86.00 (+35.82%) |
| Earnings Date | Feb 5, 2026 |
About HAE
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.... [Read more]
Financial Performance
In fiscal year 2025, Haemonetics's revenue was $1.36 billion, an increase of 3.95% compared to the previous year's $1.31 billion. Earnings were $167.68 million, an increase of 42.64%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for HAE stock is "Buy." The 12-month stock price target is $86.0, which is an increase of 35.82% from the latest price.
News
Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology
BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today an...
Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference
BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th An...
The London Company Small Cap Q4 2025 Performance And Trades
The London Company Small Cap portfolio increased 2.7% (2.5% net) during the quarter vs. a 2.2% increase in the Russell 2000 Index. Contributors to relative performance were White Mountains Insurance G...
These Analysts Revise Their Forecasts On Haemonetics After Q3 Earnings
Haemonetics Corporation (NYSE: HAE) reported upbeat earnings for its third quarter on Thursday.
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q3 2026 Earnings Call Transcript
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal...
Allspring Common Stock Fund Q4 2025 Performance Review
In the fourth quarter, Revolve's stock rose as its revenue met expectations with a 4.4% year-over-year increase. In fiscal second quarter 2026, Haemonetics delivered strong performance, raising guidan...
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics
$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic ho...
Vivasure Medical Announces Acquisition by Haemonetics Corporation
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemo...
Haemonetics Acquires Vivasure Medical Limited
BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today ann...
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2026 Results: February 5, 2026
BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Febru...
Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francis...
Earn Twice The Yield You Get From Bank On HAE Stock
Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.
Top 2 Health Care Stocks You May Want To Dump This Month
As of Dec. 2, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Touchstone Small Company Fund Q3 2025 Performance Review
The Touchstone Small Company Fund underperformed its benchmark, the Russell 2000 Index, for the quarter ended September 30, 2025. Among the Fund's top-performing sectors in terms of adding value were ...
Touchstone Small Cap Fund Q3 2025 Contributors And Detractors
Among the largest contributors to Fund performance were Armstrong World Industries, Ingevity Corporation, and Graham Holdings Co. Graham Holdings outperformed the benchmark on strong second quarter re...
Haemonetics Is Still Undervalued, Even After The Rally
Haemonetics Corporation remains a Buy, supported by robust profit margins, strong cash flow, and leading TEG and plasma businesses driving organic growth. HAE reported improved gross and operating mar...
The London Company Small Cap Q3 2025 Performance Update
The London Company Small Cap portfolio increased 1.9% gross (1.6% net) during the quarter vs. a 12.4% increase in the Russell 2000 Index. Armstrong World Industries' shares outperformed in the quarter...
Haemonetics Corporation (HAE) Q2 2026 Earnings Call Transcript
Haemonetics Corporation ( HAE) Q2 2026 Earnings Call November 6, 2025 8:00 AM EST Company Participants Olga Guyette - Senior Director of Investor Relations Christopher Simon - CEO, President & Direct...
Haemonetics Corporation Announces Second Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON , Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fisc...
Victory Sycamore Small Company Opportunity Fund Q3 2025 Top Contributors And Detractors
Supply has tightened over the past few years, setting NAND up for strong demand and pricing amid constrained supply. TSEM produces Silicon Photonics chips that are used in optical transceivers, which ...
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2026 Results: November 6, 2025
BOSTON , Oct. 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, Nov...
I'm Recommending Haemonetics Again, But With Caveats (Ratings Upgrade)
Haemonetics Corporation remains a high-quality blood-management franchise with strong TEG and plasma software moats, but recent growth has paused due to portfolio shifts and competition. Q1 FY2026 res...
Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Christopher A. Simon - CEO, President & Director James C.